News

The Company expects patient recruitment in the second Phase 3 trial investigating Fovista in combination with Lucentis to be completed approximately by the end of the third quarter

Previously, Curemark announced the successful results of its FDA Phase III double blinded clinical trial for CM-AT in children ages 3-8 with Autism who had low levels of

OSE CEO Dominique Costantini said: "This collaboration represents a significant step as first licensing and distribution agreement in the business development strategy for OSE Pharma with pharmaceutical companies

Patient enrolment is expected to be initiated shortly in this trial, which allows the company to combine its HS-110 with multiple immune modulating strategies. HS-110 is the company’s

With the acquisition, Juno will now have access to transformative cell selection and activation capabilities, advanced manufacturing automation, improved supply chain and lower expected cost of goods. According

Amitiza is a chloride channel activator that acts locally in the small intestine to restore motility and to address the underlying pathophysiology and secondary symptoms of constipation. Under

Under the deal, the parties will explore and test the value of digital health solutions, mobile technologies and insights from advanced data analytics in the delivery of health

The PMA application seeks approval for tumor treating fields (TTFields), in combination with temozolomide chemotherapy, as a first-line treatment for glioblastoma (GBM). The submission of PMA is based

Objective of the project is to use power of the body’s own immune system to attack cancer cells and discover possible new treatment options for cancer patients. By